Chapter 4 - Confrontation
An alarm that was not set becomes useless, no matter how much you blame it for not waking you. His drowsy eyes glance at the clock: 11:31. Shit! Forgot to set the alarm again! The bathroom became a ‘processing’ room as Mike went quickly through the paces…Once again, cream was applied; the razor slid through hair like a tractor slicing through wheat in a field.
Dammit! I really hate being in a hurry! The coffee machine felt rushed and manhandled. The slamming microwave door startled the poor burrito. Even milk was spilled without its consent. Mike managed to gather his notes from last night, especially those with important questions.
One burrito gone, he ran out the door, got on the B35 bus, and boarded the subway to City Hall. On the train he checked for his Philips voice recorder and missed a heartbeat! It was not in his blazer pocket! Relief! He found it tucked in the outside pocket of his backpack. Dam! This is my best proof collector! I cant risk losing it again!
This feels like my first assignment. Thought Mike.
His nervousness was palpable. Even the morning burrito felt unhappy. Getting early to City Hall was critical to secure a good spot. He remembered traveling to the New Jersey City Hall. He was running late and practically ran up the steps, slipping and twisting his left ankle. Someone from City Hall got him a chair. He spent the entire news conference sitting and unable to take pictures.
This time he will be careful and make sure that he is close enough to Dr. Kline. He managed to secure a spot on the left flank of the steps. He was the only reporter using a Leica Digi Lux 3 with cheap Olympus pancake lenses, while most of the other reporters were using expensive Canon or Nikon cameras. But he didn't care. His camera was a special gift from his father when he turned 18. It's the only camera he has ever used throughout his career. He does have one set of Olympus High Zoom lenses, which he bought in 2006 after getting paid for a major story.
Mike Carter’s pen hovered above his notepad as the historic double doors of City Hall creaked open. A hush rippled through the assembled press corps, broken only by the soft click of cameras warming up. Then, like a corporate tide, Dr. Kline’s entourage poured out: a phalanx of navy-blue suits, each tailored stitch whispering of boardroom power.
At the front, a lean woman in a charcoal pantsuit clutched a leather-bound briefing folder stamped with the Glurelix logo. Behind her, lobbyists in pinstriped three-pieces exchanged curt nods, their gold cufflinks catching the midday sun. A wave of excitement pulsed through Mike’s chest as he noted their crisp posture and the silent choreography of their advance, with each footstep measured, deliberate, confident.
One of the lobbyists paused on the top step, raised a hand in a half-salute to the gathering cameras, and set the tone for what was to come; formality laced with corporate ambition. The air crackled with anticipation, and Mike pressed record on his voice recorder, ready to capture every nuanced word and clipped exchange before Dr. Kline herself emerged. What a bunch of actors we have here. Thought Mike. “Hey, hey, watch it, brother.” Snapped Mike as another reporter tried to get in front of him. “Oh, sorry man. It's my bad.” Said the guy.
Mike just couldn't believe his eyes. It was James from the Daily Beast. They had worked together on so many stories back then. “James, it's me, Mike!”
“Wow! Mikey, what are you doing here, man?”
“Well, I was about to ask you the same thing,” Said Mike.
“I was sent here by the Daily… to cover this. Who are you with?” Said James.
“I'm also with The Daily Beast. Who sent you here?”
“Jones…Jones sent me here. And who sent you?”
“It was Jones, also.” Next, Dr. Kline approached the podium.
“Good afternoon and thank you all for joining us on this momentous day. After extensive research and negotiations with our new partner, SyndoMere Labs, we are thrilled to introduce Betoforin, the first generic equivalent to Glurelix. This achievement represents years of scientific collaboration, regulatory diligence, and a shared commitment to affordable patient care.
I’m proud to report that the FDA granted approval for Betoforin five weeks ago, following rigorous clinical evaluations that confirmed its safety and efficacy. Today marks the culmination of that process, and I’m pleased to announce that beginning this coming Monday, major pharmacy chains across all five boroughs will start stocking Betoforin on their shelves.
Our national rollout is slated to begin within two months, on February 24th, to be exact. We’ve worked closely with SyndoMere Labs’ Newark facility, which has already doubled its production capacity to meet the anticipated demand. Representatives from that facility are joining me onstage today, and I invite them to share further details about our expanded manufacturing operations.
Betoforin isn’t just another generic; it’s a testament to what happens when innovation meets partnership. Together, we are lowering costs, expanding access, and ushering in a new era of diabetes management for millions of patients. And now, I’d like to introduce you to Jorge Ramirez. He has been a long-time Glurelix user who is excited to finally be able to afford a less expensive alternative named Betoforin.”
Jorge Ramirez’s hands trembled as he stepped up to the polished podium, the glare of camera lights catching the beads of sweat on his forehead. He cleared his throat, heart pounding against the lapels of his navy blazer; his pants too stiff for this kind of performance. Behind him, the SyndoMere reps exchanged polite nods, oblivious to the fib he was about to tell.
“Good afternoon,” he began, voice slightly wavering but gaining strength with each word. “I’ve been managing my diabetes on Glurelix for years, but as a freelance delivery driver, the cost has always been a heavy burden. With Betoforin coming online next week, I’m thrilled to finally keep more of my paycheck and still get the treatment I need.”
He paused, offering a rehearsed smile to the assembled press. In truth, Jorge only injects insulin sporadically and has been receiving Glurelix through a low-income assistance program, but no one in the crowd needed to know that. What mattered today was the story of a struggling patient saved by a cheaper alternative, and he leaned into it, every nervous syllable serving the narrative Dr. Kline had crafted for him.
The crowd of spectators applauded as the relentless click of cameras filled the air and the flashes of light had Jorge blinking incessantly.
Mike quickly slipped the first question to Dr. Kline.
“Dr. Kline, can you confirm that the active‐pharmaceutical‐ingredient purity in Betoforin matches Glurelix? There must be a reason why it is so much cheaper.” Mike’s intense green eyes did not blink, which caught Dr. Kline off guard.
“Thank you for that question. I can confirm that Betoforin’s active pharmaceutical ingredient purity meets the same 99.8 percent standard established for Glurelix. Every batch undergoes the same chromatographic and spectrometric analyses required by the FDA, and independent third-party labs have verified that our impurity profile is indistinguishable from that of the brand-name product. The cost reduction you’re seeing isn’t due to lower quality; it reflects significant process innovations and economies of scale. By partnering with SyndoMere Labs, we implemented continuous-flow reactors, optimized raw-material procurement, and expanded to multi-shift production runs at their Newark facility. Those efficiencies drive down per-dose manufacturing costs without ever compromising on purity, stability, or patient safety.”
Unknown to Mike, two men dressed in black were taking notice of Mike's questioning. But they were not there for Mike. They were there to intimidate Jorge; to make sure that he said what he was being paid to say. Then Mike quickly followed up with, “Dr. Kline, I don't believe you.”
That remark totally caught Dr. Kline off guard! But as a woman who thinks on her feet, she countered with,
“I’m sorry, and you are?”
“Mike Carter with The Daily Beast.”
“Ah, yes, Mr. Carter with the Daily Beast. So, what aspect of Betoforin’s release do you not believe?”
“Everything, your so-called meticulous research and so on.”
Dr. Kline smiled with the practiced composure of someone who’d weathered tougher interrogations.
“Mr. Carter, I understand skepticism; that’s healthy in journalism. We published full study data, filed all required documentation with the FDA, and engaged independent labs to validate our findings. If you have specific concerns about methods or impurity profiles, name them, and I’ll have the relevant reports provided to your office. Additionally, I would like to note that we adhered to FDA guidance at every step and maintained complete chain-of-custody records for all batches. Allegations of corner-cutting are serious. If you possess evidence to support that claim, submit it; we’ll cooperate with regulators and counsel. Until then, I stand by the company’s compliance and the safety of Betoforin.” I wish I hadn’t had to go down that rabbit hole! She thought.
At that moment, James was gesturing to Mike to quit that line of questioning. Mike nodded and shouted to Dr. Kline, “Thank you.” Then he turned to James and said, “What’s wrong? That's what we are here for!”
“You want to get us fired? This is just a press announcement, not a follow-up to a scandal.”
Mike threw up a hand, then dropped it just as fast. Forget it. He thought. After a few more questions from other reporters, the news conference was over. But before the corporate entourage retired behind the City Hall doors, Dr. Kline whispered to one of her assistants, “That Black reporter with those weird green eyes, assign a team to find out what he knows or doesn’t know about our products.”